{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T14:26:17Z","timestamp":1652624777012},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2004,12,1]],"date-time":"2004-12-01T00:00:00Z","timestamp":1101859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2004,12]]},"DOI":"10.1007\/s00105-004-0844-y","type":"journal-article","created":{"date-parts":[[2004,11,2]],"date-time":"2004-11-02T13:15:44Z","timestamp":1099401344000},"page":"1150-1153","source":"Crossref","is-referenced-by-count":3,"title":["Behandlung therapieresistenter akraler Ulzera mit Iloprost"],"prefix":"10.1007","volume":"55","author":[{"given":"S.","family":"von Schmiedeberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Artik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Assmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Megahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ruzicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/ard.49.11.926","volume":"49","author":"Casas","year":"1990","unstructured":"Casas JA, Saway PA, Villareal I, Nolte C (1990) 5-fluoro-uracil in the treatment of scleroderma: a randomized, double-blind, placebo-controlled international collaborative study. Ann Rheum Dis 49:926?931","journal-title":"Ann Rheum Dis"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00002281-199511000-00009","volume":"7","author":"Clements","year":"1995","unstructured":"Clements PJ (1995) Measuring disease activity and severity in scleroderma. Curr Opin Rheumatol 7:517?551","journal-title":"Curr Opin Rheumatol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"606","DOI":"10.7326\/0003-4819-114-7-606_1","volume":"114","author":"Constans","year":"1991","unstructured":"Constans T, Diot E, Lasfregues G (1991) Iloprost for scleroderma. Letter. Ann Intern Med 114:606","journal-title":"Ann Intern Med"},{"key":"CR4","first-page":"739","volume":"83","author":"Cordioli","year":"1992","unstructured":"Cordioli E, Virgilio S, Ghirardi R, Martinelli M (1992) Effects of long- term iloprost therapy on Raynaud?s phenomenon in progressive systemic sclerosis. Minerva Med 83:739?744","journal-title":"Minerva Med"},{"key":"CR5","first-page":"446","volume":"271","author":"Crutchley","year":"1994","unstructured":"Crutchley DJ, Conanan LB, Que BG (1994) Effects of prostacyclin analogues on the synthesis of tissue factor, tumor necrosis factor-alpha and interleukin-1 beta in human monocytic THP-1 cells. J Pharmacol Exp Ther 271:446?451","journal-title":"J Pharmacol Exp Ther"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0090-6980(01)00131-9","volume":"65","author":"Della Bella","year":"2001","unstructured":"Della Bella S, Molteni M, Mocellin C et al. (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Lipid Mediators 65:73?83","journal-title":"Prostaglandins Lipid Mediators"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/anr.1780320512","volume":"32","author":"Furst","year":"1989","unstructured":"Furst DE, Clements PJ, Hillis S et al. (1989) Immunosuppression with chlorambucil vs placebo for scleroderma: results of a three year, parallel, randomized, double-blind study. Arthritis Rheum 32:584?589.","journal-title":"Arthritis Rheum"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/art.1780330508","volume":"33","author":"Genth","year":"1990","unstructured":"Genth E, Mierau R, Genetzky P et al. (1990) Immunogenetic association of scleroderma-related antinuclear antibodies. Arthritis Rheum 33:657?665","journal-title":"Arthritis Rheum"},{"key":"CR9","unstructured":"Gr\u00f6chenig E (2002) Gef\u00e4\u00dfmedizin. ABW Wissenschaftsverlag, Berlin Leiben, S 94?96"},{"key":"CR10","first-page":"1496","volume":"18","author":"Jimenez","year":"1991","unstructured":"Jimenez SA, Sigal SH (1991) A 15 year-prospective study of treatment of rapidly, progressive systemic sclerosis with D-penicillamine. J Rheumatol 18:1496?1501","journal-title":"J Rheumatol"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.1780380102","volume":"38","author":"Kahaleh","year":"1995","unstructured":"Kahaleh B, Matucci-Cerinic M (1995) Raynaud?s phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 38:1?4","journal-title":"Arthritis Rheum"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0190-9622(88)70070-5","volume":"18","author":"Krieg","year":"1988","unstructured":"Krieg T, Meurer M (1988) Systemic scleroderma. Clinical and pathophysiologic aspects. J Am Acad Dermatol 18:457?481","journal-title":"J Am Acad Dermtol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/ard.51.2.286","volume":"51","author":"LeRoy","year":"1992","unstructured":"LeRoy EC (1992) A brief overview of the pathogenesis of scleroderma (systemic sclerosis). Ann Rheum Dis 51:286?288","journal-title":"Ann Rheum Dis"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/pgmj.63.742.617","volume":"63","author":"Rademaker","year":"1987","unstructured":"Rademaker M, Thomas RHM, Provost G et al. (1987) Prolonged increased blood flow following iloprost infusion in systemic sclerosis. Postgrad Med J 63:617?620","journal-title":"Postgrad Med J"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","volume":"298","author":"Rademaker","year":"1989","unstructured":"Rademaker M, Almond NE, Beachman JA et al. (1989) Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud?s phenomenon in patients with systemic sclerosis: a double blind randomised study. Br Med J 298:561?564","journal-title":"Br Med J"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s003930050070","volume":"57","author":"Riemekasten","year":"1998","unstructured":"Riemekasten G, Jepsen H, Burmester GR, Hiepe F (1998) Iloprostgabe \u00fcber 21\u00a0Tage als wirksame Therapie bei der progressiven systemischen Sklerodermie?Fallbeschreibung und Literatur\u00fcbersicht. Z Rheumatol 57:118?124","journal-title":"Z Rheumatol"},{"key":"CR17","first-page":"431","volume":"16","author":"Righi","year":"2002","unstructured":"Righi A, Matucci Cerinic M (2002) New treatments in scleroderma: the rheumatologic perspective. JEADV 16:431?432","journal-title":"JEADV"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00005792-198011000-00001","volume":"59","author":"Rodnan","year":"1980","unstructured":"Rodnan RP, Myerowitz RL, Justh GO (1980) Morphologic changes in digital arteries of progressive systemic sclerosis (scleroderma) and Raynaud?s phenomenon. Medicine 59:393?408","journal-title":"Medicine"},{"key":"CR19","first-page":"673","volume":"19","author":"Seibold","year":"1992","unstructured":"Seibold JR, Furst DE, Clements PJ (1992) Why everything (or nothing) seems to work in the treatment of scleroderma. J Rheumatol 19:673?667","journal-title":"J Rheumatol"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/13543784.10.1.31","volume":"101","author":"Wighley","year":"2001","unstructured":"Wighley FM, Sule SD (2001) Novel therapy in the treatment of scleroderma. Exp Opin Invest Drug 101:31?48","journal-title":"Exp Opin Invest Drug"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-004-0844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-004-0844-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-004-0844-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:37:03Z","timestamp":1558568223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-004-0844-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s00105-004-0844-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}